Silo Pharma Updates Strategic Agreement with Fireblocks to Secure Crypto Treasury Management
Silo Pharma (Nasdaq: SILO), a developmental-stage biopharmaceutical and cryptocurrency treasury company, has initiated implementation of its strategic agreement with Fireblocks for crypto treasury management. Fireblocks, a leading digital asset custody platform, has facilitated over $10 trillion in secure transfers to date.
The partnership aims to establish institutional-grade infrastructure for buying, staking, and managing digital assets at scale. Fireblocks' multi-layer security framework incorporates multi-party computation technology, Intel SGX, a signature policy engine, and deposit address authentication network.
Silo Pharma (Nasdaq: SILO), una società biotecnologica in fase di sviluppo e di tesoreria di criptovalute, ha avviato l'implementazione del suo accordo strategico con Fireblocks per la gestione della tesoreria crypto. Fireblocks, una piattaforma leader per la custodia di asset digitali, ha facilitato oltre 10 trilioni di dollari in trasferimenti sicuri ad oggi.
La partnership punta a creare un'infrastruttura di livello istituzionale per l'acquisto, lo staking e la gestione degli asset digitali su larga scala. Il framework di sicurezza a più livelli di Fireblocks integra la tecnologia di calcolo multi-partito, Intel SGX, un motore di policy di firma e una rete di autenticazione degli indirizzi di deposito.
Silo Pharma (Nasdaq: SILO), una empresa en fase de desarrollo de biopharma y tesorería de criptomonedas, ha iniciado la implementación de su acuerdo estratégico con Fireblocks para la gestión de la tesorería cripto. Fireblocks, una plataforma líder de custodia de activos digitales, ha facilitado más de 10 billones de dólares en transferencias seguras hasta la fecha.
La asociación tiene como objetivo establecer una infraestructura de grado institucional para comprar, hacer staking y gestionar activos digitales a gran escala. El marco de seguridad multicapa de Fireblocks incorpora tecnología de cálculo multipartito, Intel SGX, un motor de políticas de firma y una red de autenticación de direcciones de depósito.
Silo Pharma (Nasdaq: SILO), 개발 단계의 생물의약품 및 암호화폐 금고 회사를 운영하는 기업은 암호 화폐 금고 관리에 관한 전략적 계약의 이행을 시작했습니다. Fireblocks는 디지털 자산 보관의 선도 플랫폼으로, 지금까지 10조 달러가 넘는 보안 전송을 촉진해 왔습니다.
파트너십은 대규모로 디지털 자산을 매입, 스테이킹 및 관리하기 위한 기관급 인프라를 구축하는 것을 목표로 합니다. Fireblocks의 다층 보안 프레임워크는 다당사 계산 기술, Intel SGX, 서명 정책 엔진, 예치 주소 인증 네트워크를 포함합니다.
Silo Pharma (Nasdaq : SILO), une société biopharmaceutique en développement et de trésorerie de crypto-monnaies, a commencé la mise en œuvre de son accord stratégique avec Fireblocks pour la gestion de la trésorerie cryptographique. Fireblocks, une plateforme de garde d’actifs numériques de premier plan, a facilité à ce jour plus de 10 trillions de dollars en transferts sécurisés.
Le partenariat vise à établir une infrastructure de niveau institutionnel pour l’achat, le staking et la gestion d’actifs numériques à grande échelle. Le cadre de sécurité multicouche de Fireblocks intègre la technologie de calcul multipartite, Intel SGX, un moteur de politique de signature et un réseau d’authentification des adresses de dépôt.
Silo Pharma (Nasdaq: SILO), ein in der Entwicklungsphase befindliches Biopharma- und Krypto-Tresorunternehmen, hat die Umsetzung seiner strategischen Vereinbarung mit Fireblocks für das Crypto-Treasury-Management eingeleitet. Fireblocks, eine führende Plattform zur Verwahrung digitaler Vermögenswerte, hat bisher Transfers in Höhe von über 10 Billionen Dollar ermöglicht.
Die Partnerschaft zielt darauf ab, eine institutionelle Infrastruktur für den groß angelegten Kauf, das Staking und die Verwaltung digitaler Vermögenswerte zu schaffen. Fireblocks' mehrschichtiger Sicherheitsrahmen integriert Multi-Party-Computing-Technologie, Intel SGX, eine Signatur-Policy-Engine und ein Netzwerk zur Authentifizierung von Einzahlungsadressen.
سيلو فارما (نيسداك: SILO)، شركة أدوية حيوية قيد التطوير وتخزين أموال العملات المشفرة، بدأت في تنفيذ اتفاقها الاستراتيجي مع Fireblocks لإدارة خزائن العملة الرقمية. Fireblocks، منصة حماية الأصول الرقمية الرائدة، سهلت حتى الآن تحويلات آمنة تفوق 10 تريليون دولار.
يهدف الشراكة إلى إنشاء بنية تحتية بمستوى مؤسسي للشراء، وتخزين وتحريك وإدارة الأصول الرقمية على نطاق واسع. إطار الأمان متعدد الطبقات لدى Fireblocks يدمج تقنية الحوسبة متعددة الأطراف، وIntel SGX، ومُشغِّل سياسات التوقيع، وشبكة مصادقة عناوين الإيداع.
Silo Pharma（纳斯达克：SILO），一家处于开发阶段的生物制药及加密货币金库公司，已启动与 Fireblocks 就加密资产金库管理的战略协议的实施。Fireblocks 是领先的数字资产托管平台，迄今已促成超过 10 万亿美元 的安全转账。
该伙伴关系旨在建立用于大规模购买、质押和管理数字资产的机构级基础设施。Fireblocks 的多层安全框架结合了多方计算技术、Intel SGX、签名策略引擎，以及存款地址认证网络。
- Partnership with Fireblocks, a proven leader that has processed over $10 trillion in digital asset transfers
- Implementation of institutional-grade security infrastructure for crypto treasury management
- Potential exposure to volatile cryptocurrency markets
- Deviation from traditional pharmaceutical business model into crypto assets
Fireblocks is a globally recognized leader in the digital assets space, facilitating the secure transfer of more than
SARASOTA, FL, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, announced that it has begun implementing its strategic agreement with Fireblocks, an enterprise platform for secure digital asset custody, settlement, trading operations, and stablecoin payments, to provide institutional-grade infrastructure for its crypto treasury management platform\.
Eric Weisblum, CEO of Silo, commented, “Fireblocks brings unmatched expertise and a proven track record to help Silo implement our treasury strategy. Together, we have begun building an institutional-grade infrastructure with the technology and safeguards needed to buy, stake, and manage digital assets at scale.”
Fireblocks is a globally recognized leader in the digital assets space, having facilitated the secure transfer of more than
About Silo Pharma
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories. silopharma.com
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.
Contact
800-705-0120
investors@silopharma.com
FAQ
What is the purpose of Silo Pharma's (SILO) agreement with Fireblocks?
How much in digital assets has Fireblocks processed to date?
What security features does Fireblocks provide to Silo Pharma (SILO)?
What is Silo Pharma's (SILO) current business model?
